カテゴリ： Market Monitor Global, 世界, 医療/バイオ

生物学的ワクチン補助剤のグローバル市場展望 2023年-2029年：アルミニウム製補助剤、エマルション補助剤、その他

■ 英語タイトル：Biological Vaccines Adjuvants Market, Global Outlook and Forecast 2023-2029

調査会社Market Monitor Global社が発行したリサーチレポート（データ管理コード：MMG23JU5716）■ 発行会社/調査会社：Market Monitor Global
■ 商品コード：MMG23JU5716
■ 発行日：2023年6月
■ 調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
■ 産業分野：医薬品＆医療
■ ページ数：121
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥474,500見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥616,850見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥711,750見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Market Monitor Global社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[生物学的ワクチン補助剤のグローバル市場展望 2023年-2029年：アルミニウム製補助剤、エマルション補助剤、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査レポートは次の情報を含め、世界の生物学的ワクチン補助剤市場規模と予測を収録しています。・世界の生物学的ワクチン補助剤市場：売上、2018年-2023年、2024年-2029年
・世界の生物学的ワクチン補助剤市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の生物学的ワクチン補助剤市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「アルミニウム製補助剤」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

生物学的ワクチン補助剤のグローバル主要企業は、GSK、 Dynavax Technologies、 Novavax、 Agenus、 Croda International、 Seppic、 OZ Biosciences、 Phibro Animal Health Corporation、 Associated British Foods、 InvivoGen、 Merck KGaA、 CSL Limited、 Vertellus、 Allergy Therapeutics、 Riboxx GmbH、 CaPtivatϵ Pharmaceuticals、 EuBiologics、 Pacific GeneTech、 Hawaii Biotech、 Vaxine Pty Ltd.、 Creative Diagnostics、 LiteVax BV、 Mukta Industries、 Oncovir、 TiterMax USAなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、生物学的ワクチン補助剤のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の生物学的ワクチン補助剤市場：タイプ別、2018年-2023年、2024年-2029年
世界の生物学的ワクチン補助剤市場：タイプ別市場シェア、2022年
・アルミニウム製補助剤、エマルション補助剤、その他

世界の生物学的ワクチン補助剤市場：用途別、2018年-2023年、2024年-2029年
世界の生物学的ワクチン補助剤市場：用途別市場シェア、2022年
・ヒトワクチン、動物ワクチン

世界の生物学的ワクチン補助剤市場：地域・国別、2018年-2023年、2024年-2029年
世界の生物学的ワクチン補助剤市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における生物学的ワクチン補助剤のグローバル売上、2018年-2023年
・主要企業における生物学的ワクチン補助剤のグローバル売上シェア、2022年
・主要企業における生物学的ワクチン補助剤のグローバル販売量、2018年-2023年
・主要企業における生物学的ワクチン補助剤のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
GSK、 Dynavax Technologies、 Novavax、 Agenus、 Croda International、 Seppic、 OZ Biosciences、 Phibro Animal Health Corporation、 Associated British Foods、 InvivoGen、 Merck KGaA、 CSL Limited、 Vertellus、 Allergy Therapeutics、 Riboxx GmbH、 CaPtivatϵ Pharmaceuticals、 EuBiologics、 Pacific GeneTech、 Hawaii Biotech、 Vaxine Pty Ltd.、 Creative Diagnostics、 LiteVax BV、 Mukta Industries、 Oncovir、 TiterMax USA

*************************************************************

・調査・分析レポートの概要
生物学的ワクチン補助剤市場の定義
市場セグメント
世界の生物学的ワクチン補助剤市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の生物学的ワクチン補助剤市場規模
世界の生物学的ワクチン補助剤市場規模：2022年 VS 2029年
世界の生物学的ワクチン補助剤市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの生物学的ワクチン補助剤の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の生物学的ワクチン補助剤製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：アルミニウム製補助剤、エマルション補助剤、その他
生物学的ワクチン補助剤のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：ヒトワクチン、動物ワクチン
生物学的ワクチン補助剤の用途別グローバル売上・予測

・地域別市場分析
地域別生物学的ワクチン補助剤市場規模 2022年と2029年
地域別生物学的ワクチン補助剤売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
GSK、 Dynavax Technologies、 Novavax、 Agenus、 Croda International、 Seppic、 OZ Biosciences、 Phibro Animal Health Corporation、 Associated British Foods、 InvivoGen、 Merck KGaA、 CSL Limited、 Vertellus、 Allergy Therapeutics、 Riboxx GmbH、 CaPtivatϵ Pharmaceuticals、 EuBiologics、 Pacific GeneTech、 Hawaii Biotech、 Vaxine Pty Ltd.、 Creative Diagnostics、 LiteVax BV、 Mukta Industries、 Oncovir、 TiterMax USA
...

An adjuvant is a substance that is formulated as part of a vaccine to enhance its ability to induce protection against infection. Adjuvants are substances added to vaccines to enhance the immunogenicity of highly purified antigens that have insufficient immunostimulatory capabilities, and have been used in human vaccines for more than 90 years.
This report aims to provide a comprehensive presentation of the global market for Biological Vaccines Adjuvants, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biological Vaccines Adjuvants. This report contains market size and forecasts of Biological Vaccines Adjuvants in global, including the following market information:
Global Biological Vaccines Adjuvants Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Biological Vaccines Adjuvants Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Biological Vaccines Adjuvants companies in 2022 (%)
The global Biological Vaccines Adjuvants market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Aluminum Adjuvant Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Biological Vaccines Adjuvants include GSK, Dynavax Technologies, Novavax, Agenus, Croda International, Seppic, OZ Biosciences, Phibro Animal Health Corporation and Associated British Foods, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Biological Vaccines Adjuvants manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Biological Vaccines Adjuvants Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Biological Vaccines Adjuvants Market Segment Percentages, by Type, 2022 (%)
Aluminum Adjuvant
Emulsions Adjuvant
Others
Global Biological Vaccines Adjuvants Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Biological Vaccines Adjuvants Market Segment Percentages, by Application, 2022 (%)
Human Vaccine
Veterinary Vaccine
Global Biological Vaccines Adjuvants Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Biological Vaccines Adjuvants Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Biological Vaccines Adjuvants revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Biological Vaccines Adjuvants revenues share in global market, 2022 (%)
Key companies Biological Vaccines Adjuvants sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Biological Vaccines Adjuvants sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
GSK
Dynavax Technologies
Novavax
Agenus
Croda International
Seppic
OZ Biosciences
Phibro Animal Health Corporation
Associated British Foods
InvivoGen
Merck KGaA
CSL Limited
Vertellus
Allergy Therapeutics
Riboxx GmbH
CaPtivatϵ Pharmaceuticals
EuBiologics
Pacific GeneTech
Hawaii Biotech
Vaxine Pty Ltd.
Creative Diagnostics
LiteVax BV
Mukta Industries
Oncovir
TiterMax USA
Outline of Major Chapters:
Chapter 1: Introduces the definition of Biological Vaccines Adjuvants, market overview.
Chapter 2: Global Biological Vaccines Adjuvants market size in revenue and volume.
Chapter 3: Detailed analysis of Biological Vaccines Adjuvants manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Biological Vaccines Adjuvants in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Biological Vaccines Adjuvants capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Introduction to Research & Analysis Reports
1.1 Biological Vaccines Adjuvants Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Biological Vaccines Adjuvants Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Biological Vaccines Adjuvants Overall Market Size
2.1 Global Biological Vaccines Adjuvants Market Size: 2022 VS 2029
2.2 Global Biological Vaccines Adjuvants Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Biological Vaccines Adjuvants Sales: 2018-2029
3 Company Landscape
3.1 Top Biological Vaccines Adjuvants Players in Global Market
3.2 Top Global Biological Vaccines Adjuvants Companies Ranked by Revenue
3.3 Global Biological Vaccines Adjuvants Revenue by Companies
3.4 Global Biological Vaccines Adjuvants Sales by Companies
3.5 Global Biological Vaccines Adjuvants Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Biological Vaccines Adjuvants Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Biological Vaccines Adjuvants Product Type
3.8 Tier 1, Tier 2 and Tier 3 Biological Vaccines Adjuvants Players in Global Market
3.8.1 List of Global Tier 1 Biological Vaccines Adjuvants Companies
3.8.2 List of Global Tier 2 and Tier 3 Biological Vaccines Adjuvants Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Biological Vaccines Adjuvants Market Size Markets, 2022 & 2029
4.1.2 Aluminum Adjuvant
4.1.3 Emulsions Adjuvant
4.1.4 Others
4.2 By Type – Global Biological Vaccines Adjuvants Revenue & Forecasts
4.2.1 By Type – Global Biological Vaccines Adjuvants Revenue, 2018-2023
4.2.2 By Type – Global Biological Vaccines Adjuvants Revenue, 2024-2029
4.2.3 By Type – Global Biological Vaccines Adjuvants Revenue Market Share, 2018-2029
4.3 By Type – Global Biological Vaccines Adjuvants Sales & Forecasts
4.3.1 By Type – Global Biological Vaccines Adjuvants Sales, 2018-2023
4.3.2 By Type – Global Biological Vaccines Adjuvants Sales, 2024-2029
4.3.3 By Type – Global Biological Vaccines Adjuvants Sales Market Share, 2018-2029
4.4 By Type – Global Biological Vaccines Adjuvants Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Biological Vaccines Adjuvants Market Size, 2022 & 2029
5.1.2 Human Vaccine
5.1.3 Veterinary Vaccine
5.2 By Application – Global Biological Vaccines Adjuvants Revenue & Forecasts
5.2.1 By Application – Global Biological Vaccines Adjuvants Revenue, 2018-2023
5.2.2 By Application – Global Biological Vaccines Adjuvants Revenue, 2024-2029
5.2.3 By Application – Global Biological Vaccines Adjuvants Revenue Market Share, 2018-2029
5.3 By Application – Global Biological Vaccines Adjuvants Sales & Forecasts
5.3.1 By Application – Global Biological Vaccines Adjuvants Sales, 2018-2023
5.3.2 By Application – Global Biological Vaccines Adjuvants Sales, 2024-2029
5.3.3 By Application – Global Biological Vaccines Adjuvants Sales Market Share, 2018-2029
5.4 By Application – Global Biological Vaccines Adjuvants Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Biological Vaccines Adjuvants Market Size, 2022 & 2029
6.2 By Region – Global Biological Vaccines Adjuvants Revenue & Forecasts
6.2.1 By Region – Global Biological Vaccines Adjuvants Revenue, 2018-2023
6.2.2 By Region – Global Biological Vaccines Adjuvants Revenue, 2024-2029
6.2.3 By Region – Global Biological Vaccines Adjuvants Revenue Market Share, 2018-2029
6.3 By Region – Global Biological Vaccines Adjuvants Sales & Forecasts
6.3.1 By Region – Global Biological Vaccines Adjuvants Sales, 2018-2023
6.3.2 By Region – Global Biological Vaccines Adjuvants Sales, 2024-2029
6.3.3 By Region – Global Biological Vaccines Adjuvants Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Biological Vaccines Adjuvants Revenue, 2018-2029
6.4.2 By Country – North America Biological Vaccines Adjuvants Sales, 2018-2029
6.4.3 US Biological Vaccines Adjuvants Market Size, 2018-2029
6.4.4 Canada Biological Vaccines Adjuvants Market Size, 2018-2029
6.4.5 Mexico Biological Vaccines Adjuvants Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Biological Vaccines Adjuvants Revenue, 2018-2029
6.5.2 By Country – Europe Biological Vaccines Adjuvants Sales, 2018-2029
6.5.3 Germany Biological Vaccines Adjuvants Market Size, 2018-2029
6.5.4 France Biological Vaccines Adjuvants Market Size, 2018-2029
6.5.5 U.K. Biological Vaccines Adjuvants Market Size, 2018-2029
6.5.6 Italy Biological Vaccines Adjuvants Market Size, 2018-2029
6.5.7 Russia Biological Vaccines Adjuvants Market Size, 2018-2029
6.5.8 Nordic Countries Biological Vaccines Adjuvants Market Size, 2018-2029
6.5.9 Benelux Biological Vaccines Adjuvants Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Biological Vaccines Adjuvants Revenue, 2018-2029
6.6.2 By Region – Asia Biological Vaccines Adjuvants Sales, 2018-2029
6.6.3 China Biological Vaccines Adjuvants Market Size, 2018-2029
6.6.4 Japan Biological Vaccines Adjuvants Market Size, 2018-2029
6.6.5 South Korea Biological Vaccines Adjuvants Market Size, 2018-2029
6.6.6 Southeast Asia Biological Vaccines Adjuvants Market Size, 2018-2029
6.6.7 India Biological Vaccines Adjuvants Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Biological Vaccines Adjuvants Revenue, 2018-2029
6.7.2 By Country – South America Biological Vaccines Adjuvants Sales, 2018-2029
6.7.3 Brazil Biological Vaccines Adjuvants Market Size, 2018-2029
6.7.4 Argentina Biological Vaccines Adjuvants Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Biological Vaccines Adjuvants Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Biological Vaccines Adjuvants Sales, 2018-2029
6.8.3 Turkey Biological Vaccines Adjuvants Market Size, 2018-2029
6.8.4 Israel Biological Vaccines Adjuvants Market Size, 2018-2029
6.8.5 Saudi Arabia Biological Vaccines Adjuvants Market Size, 2018-2029
6.8.6 UAE Biological Vaccines Adjuvants Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 GSK
7.1.1 GSK Company Summary
7.1.2 GSK Business Overview
7.1.3 GSK Biological Vaccines Adjuvants Major Product Offerings
7.1.4 GSK Biological Vaccines Adjuvants Sales and Revenue in Global (2018-2023)
7.1.5 GSK Key News & Latest Developments
7.2 Dynavax Technologies
7.2.1 Dynavax Technologies Company Summary
7.2.2 Dynavax Technologies Business Overview
7.2.3 Dynavax Technologies Biological Vaccines Adjuvants Major Product Offerings
7.2.4 Dynavax Technologies Biological Vaccines Adjuvants Sales and Revenue in Global (2018-2023)
7.2.5 Dynavax Technologies Key News & Latest Developments
7.3 Novavax
7.3.1 Novavax Company Summary
7.3.2 Novavax Business Overview
7.3.3 Novavax Biological Vaccines Adjuvants Major Product Offerings
7.3.4 Novavax Biological Vaccines Adjuvants Sales and Revenue in Global (2018-2023)
7.3.5 Novavax Key News & Latest Developments
7.4 Agenus
7.4.1 Agenus Company Summary
7.4.2 Agenus Business Overview
7.4.3 Agenus Biological Vaccines Adjuvants Major Product Offerings
7.4.4 Agenus Biological Vaccines Adjuvants Sales and Revenue in Global (2018-2023)
7.4.5 Agenus Key News & Latest Developments
7.5 Croda International
7.5.1 Croda International Company Summary
7.5.2 Croda International Business Overview
7.5.3 Croda International Biological Vaccines Adjuvants Major Product Offerings
7.5.4 Croda International Biological Vaccines Adjuvants Sales and Revenue in Global (2018-2023)
7.5.5 Croda International Key News & Latest Developments
7.6 Seppic
7.6.1 Seppic Company Summary
7.6.2 Seppic Business Overview
7.6.3 Seppic Biological Vaccines Adjuvants Major Product Offerings
7.6.4 Seppic Biological Vaccines Adjuvants Sales and Revenue in Global (2018-2023)
7.6.5 Seppic Key News & Latest Developments
7.7 OZ Biosciences
7.7.1 OZ Biosciences Company Summary
7.7.2 OZ Biosciences Business Overview
7.7.3 OZ Biosciences Biological Vaccines Adjuvants Major Product Offerings
7.7.4 OZ Biosciences Biological Vaccines Adjuvants Sales and Revenue in Global (2018-2023)
7.7.5 OZ Biosciences Key News & Latest Developments
7.8 Phibro Animal Health Corporation
7.8.1 Phibro Animal Health Corporation Company Summary
7.8.2 Phibro Animal Health Corporation Business Overview
7.8.3 Phibro Animal Health Corporation Biological Vaccines Adjuvants Major Product Offerings
7.8.4 Phibro Animal Health Corporation Biological Vaccines Adjuvants Sales and Revenue in Global (2018-2023)
7.8.5 Phibro Animal Health Corporation Key News & Latest Developments
7.9 Associated British Foods
7.9.1 Associated British Foods Company Summary
7.9.2 Associated British Foods Business Overview
7.9.3 Associated British Foods Biological Vaccines Adjuvants Major Product Offerings
7.9.4 Associated British Foods Biological Vaccines Adjuvants Sales and Revenue in Global (2018-2023)
7.9.5 Associated British Foods Key News & Latest Developments
7.10 InvivoGen
7.10.1 InvivoGen Company Summary
7.10.2 InvivoGen Business Overview
7.10.3 InvivoGen Biological Vaccines Adjuvants Major Product Offerings
7.10.4 InvivoGen Biological Vaccines Adjuvants Sales and Revenue in Global (2018-2023)
7.10.5 InvivoGen Key News & Latest Developments
7.11 Merck KGaA
7.11.1 Merck KGaA Company Summary
7.11.2 Merck KGaA Biological Vaccines Adjuvants Business Overview
7.11.3 Merck KGaA Biological Vaccines Adjuvants Major Product Offerings
7.11.4 Merck KGaA Biological Vaccines Adjuvants Sales and Revenue in Global (2018-2023)
7.11.5 Merck KGaA Key News & Latest Developments
7.12 CSL Limited
7.12.1 CSL Limited Company Summary
7.12.2 CSL Limited Biological Vaccines Adjuvants Business Overview
7.12.3 CSL Limited Biological Vaccines Adjuvants Major Product Offerings
7.12.4 CSL Limited Biological Vaccines Adjuvants Sales and Revenue in Global (2018-2023)
7.12.5 CSL Limited Key News & Latest Developments
7.13 Vertellus
7.13.1 Vertellus Company Summary
7.13.2 Vertellus Biological Vaccines Adjuvants Business Overview
7.13.3 Vertellus Biological Vaccines Adjuvants Major Product Offerings
7.13.4 Vertellus Biological Vaccines Adjuvants Sales and Revenue in Global (2018-2023)
7.13.5 Vertellus Key News & Latest Developments
7.14 Allergy Therapeutics
7.14.1 Allergy Therapeutics Company Summary
7.14.2 Allergy Therapeutics Business Overview
7.14.3 Allergy Therapeutics Biological Vaccines Adjuvants Major Product Offerings
7.14.4 Allergy Therapeutics Biological Vaccines Adjuvants Sales and Revenue in Global (2018-2023)
7.14.5 Allergy Therapeutics Key News & Latest Developments
7.15 Riboxx GmbH
7.15.1 Riboxx GmbH Company Summary
7.15.2 Riboxx GmbH Business Overview
7.15.3 Riboxx GmbH Biological Vaccines Adjuvants Major Product Offerings
7.15.4 Riboxx GmbH Biological Vaccines Adjuvants Sales and Revenue in Global (2018-2023)
7.15.5 Riboxx GmbH Key News & Latest Developments
7.16 CaPtivatϵ Pharmaceuticals
7.16.1 CaPtivatϵ Pharmaceuticals Company Summary
7.16.2 CaPtivatϵ Pharmaceuticals Business Overview
7.16.3 CaPtivatϵ Pharmaceuticals Biological Vaccines Adjuvants Major Product Offerings
7.16.4 CaPtivatϵ Pharmaceuticals Biological Vaccines Adjuvants Sales and Revenue in Global (2018-2023)
7.16.5 CaPtivatϵ Pharmaceuticals Key News & Latest Developments
7.17 EuBiologics
7.17.1 EuBiologics Company Summary
7.17.2 EuBiologics Business Overview
7.17.3 EuBiologics Biological Vaccines Adjuvants Major Product Offerings
7.17.4 EuBiologics Biological Vaccines Adjuvants Sales and Revenue in Global (2018-2023)
7.17.5 EuBiologics Key News & Latest Developments
7.18 Pacific GeneTech
7.18.1 Pacific GeneTech Company Summary
7.18.2 Pacific GeneTech Business Overview
7.18.3 Pacific GeneTech Biological Vaccines Adjuvants Major Product Offerings
7.18.4 Pacific GeneTech Biological Vaccines Adjuvants Sales and Revenue in Global (2018-2023)
7.18.5 Pacific GeneTech Key News & Latest Developments
7.19 Hawaii Biotech
7.19.1 Hawaii Biotech Company Summary
7.19.2 Hawaii Biotech Business Overview
7.19.3 Hawaii Biotech Biological Vaccines Adjuvants Major Product Offerings
7.19.4 Hawaii Biotech Biological Vaccines Adjuvants Sales and Revenue in Global (2018-2023)
7.19.5 Hawaii Biotech Key News & Latest Developments
7.20 Vaxine Pty Ltd.
7.20.1 Vaxine Pty Ltd. Company Summary
7.20.2 Vaxine Pty Ltd. Business Overview
7.20.3 Vaxine Pty Ltd. Biological Vaccines Adjuvants Major Product Offerings
7.20.4 Vaxine Pty Ltd. Biological Vaccines Adjuvants Sales and Revenue in Global (2018-2023)
7.20.5 Vaxine Pty Ltd. Key News & Latest Developments
7.21 Creative Diagnostics
7.21.1 Creative Diagnostics Company Summary
7.21.2 Creative Diagnostics Business Overview
7.21.3 Creative Diagnostics Biological Vaccines Adjuvants Major Product Offerings
7.21.4 Creative Diagnostics Biological Vaccines Adjuvants Sales and Revenue in Global (2018-2023)
7.21.5 Creative Diagnostics Key News & Latest Developments
7.22 LiteVax BV
7.22.1 LiteVax BV Company Summary
7.22.2 LiteVax BV Business Overview
7.22.3 LiteVax BV Biological Vaccines Adjuvants Major Product Offerings
7.22.4 LiteVax BV Biological Vaccines Adjuvants Sales and Revenue in Global (2018-2023)
7.22.5 LiteVax BV Key News & Latest Developments
7.23 Mukta Industries
7.23.1 Mukta Industries Company Summary
7.23.2 Mukta Industries Business Overview
7.23.3 Mukta Industries Biological Vaccines Adjuvants Major Product Offerings
7.23.4 Mukta Industries Biological Vaccines Adjuvants Sales and Revenue in Global (2018-2023)
7.23.5 Mukta Industries Key News & Latest Developments
7.24 Oncovir
7.24.1 Oncovir Company Summary
7.24.2 Oncovir Business Overview
7.24.3 Oncovir Biological Vaccines Adjuvants Major Product Offerings
7.24.4 Oncovir Biological Vaccines Adjuvants Sales and Revenue in Global (2018-2023)
7.24.5 Oncovir Key News & Latest Developments
7.25 TiterMax USA
7.25.1 TiterMax USA Company Summary
7.25.2 TiterMax USA Business Overview
7.25.3 TiterMax USA Biological Vaccines Adjuvants Major Product Offerings
7.25.4 TiterMax USA Biological Vaccines Adjuvants Sales and Revenue in Global (2018-2023)
7.25.5 TiterMax USA Key News & Latest Developments
8 Global Biological Vaccines Adjuvants Production Capacity, Analysis
8.1 Global Biological Vaccines Adjuvants Production Capacity, 2018-2029
8.2 Biological Vaccines Adjuvants Production Capacity of Key Manufacturers in Global Market
8.3 Global Biological Vaccines Adjuvants Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Biological Vaccines Adjuvants Supply Chain Analysis
10.1 Biological Vaccines Adjuvants Industry Value Chain
10.2 Biological Vaccines Adjuvants Upstream Market
10.3 Biological Vaccines Adjuvants Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Biological Vaccines Adjuvants Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 経口ワクチンアジュバントのグローバル市場展望 2023年-2029年：動物用ワクチンアジュバント、人間用ワクチンアジュバント
  • 経口ポリオワクチン（OPV）のグローバル市場展望 2023年-2029年：三価OPV、二価OPV
  • 大人&小児用ワクチンのグローバル市場展望 2023年-2029年：大人用ワクチン、小児用ワクチン
  • ブルーアイ症候群ワクチンのグローバル市場展望 2023年-2029年：生ワクチン、死菌ワクチン
  • 青耳豚ワクチンのグローバル市場展望 2023年-2029年：生ワクチン、死菌ワクチン
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(MMG23JU5716 )"生物学的ワクチン補助剤のグローバル市場展望 2023年-2029年：アルミニウム製補助剤、エマルション補助剤、その他" (英文：Biological Vaccines Adjuvants Market, Global Outlook and Forecast 2023-2029)はMarket Monitor Global社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。